Calyx and Invicro are now Perceptive
Independent review of trial event assessments by adjudication experts.
Proven expertise in delivering high-quality imaging data at a global scale.
With strengths in instrument engineering, signal processing, and pharmaceutical R&D, Perceptive Discovery consistently delivers successful imaging study designs and executions.
Effective RTSM, built on 30 years of experience, and connected to an ecosystem which includes eConsent and eCOA.
Highly established imaging centers for first-in-human and multicenter trials.
900+ agents radiolabeled and counting.
Supporting both malignant and non-malignant indications.
Experts in Alzheimer’s Disease, Parkinson’s Disease imaging and more.
Supporting over 85% of radiopharmaceutical companies.
Optimize preclinical and clinical trials in other areas and drug classifications.
Therapeutic and technical expertise in imaging modalities, protocol design, and acquisition.
Oncology imaging, RTSM, and clinical adjudication services.
Tackling unique rare disease trial supply, imaging and adjudication challenges.
We are here to serve science.
From discovery, through early to late-phase clinical development, to regulatory approval and post-market, you can count on Perceptive to be dependable, diligent, and driven in everything we do.
Perceptive Discovery bridges preclinical insights to early clinical success, ensuring rigorous scientific analysis and high-quality data to support innovation.
Providing the right-fit randomization & trial supply management solution for your trials, delivered by experts.
The right people, experience, and technology to drive clinical trial imaging success.
With over 20 years of neuroimaging experience in Alzheimer’s disease (AD), Perceptive is a leader in advancing PET and MRI imaging biomarkers for drug development and clinical research. Our global multi-center imaging trial management services include radiotracer supply, centralized data management, and advanced analysis as well as visual reads of imaging endpoints.
Developing novel CNS therapies is a complex endeavor, requiring scientific rigor, medical expertise, and operational excellence. Our proven track record in supporting CNS studies reflects our commitment to transforming healthcare through innovative imaging and informatics.
AD imaging trials managed
subjects imaged
AD imaging studies
multi-center Phase II-III trials
Perceptive provides a broad range of imaging endpoints and advanced image analytics for Alzheimer’s research:
Amyloid-β (Aβ) and tau are pivotal biomarkers in AD clinical trials due to their central role in disease pathogenesis. Utilizing specific PET radioligands, we measure misfolded protein concentrations to provide imaging endpoints for patient stratification and pharmacodynamic assessments, enabling enhanced decision-making in drug development.
Developed through the spatio-temporal analysis of extensive neuroimaging datasets, AmyloidIQ quantifies the global amyloid burden in the brain. It surpasses other amyloid quantification algorithms in both stratifying subjects for clinical trials and monitoring therapeutic interventions.
Building on AmyloidIQ’s framework, TauIQ quantifies both global and local tau deposition, addressing the complexity of tau accumulation in AD. It outperforms SUVr methods in cross-sectional and longitudinal analyses.
Over two decades of specialized experience in imaging biomarkers for AD.
Cutting-edge tools like AmyloidIQ and TauIQ as well as advanced MRI approaches for superior analysis and decision-making.
From early-phase trials to late-stage studies, we provide end-to-end support for imaging and biomarker development.
A robust radiotracer supply network coupled with global imaging footprint to serve the sites and the study teams.
We work closely with academic institutions, pharmaceutical companies, and research organizations to drive progress.
Reach out today and one of our solution experts will be in touch to learn about your specific needs.
